Cisplatin (Platinol ®) Archives

Clinical Lung Cancer 2020 July 3 [Link] Arkadiusz Z Dudek, Xiaofei Wang, Lin Gu, Stephanie Duong, Thomas E Stinchcombe, Robert Kratzke, Hossein Borghaei, Everett E Vokes, Hedy L Kindler Abstract Background: The role of maintenance therapy for malignant pleural mesothelioma (MPM) is unknown. We performed a randomized phase II trial to determine if continuation of…

Clinical Cancer Research 2020 July 15 [Link] Dean A Fennell, Sarah Danson, Penella J Woll, Martin Forster, Denis Talbot, Jennifer Child, Laura Farrelly, Annabel Sharkey, Sara Busacca, Yenting Ngai, Allan Hackshaw, Graham M Wheeler Abstract Purpose: Ganetespib, a highly potent, small-molecule Heatshock protein 90 inhibitor, has potential efficacy in malignant pleural mesothelioma (MPM) via activity…

Medicine 2020 May 29 [Link] Hiroaki Ikushima, Toshio Sakatani, Sayaka Ohara, Hideyuki Takeshima, Hajime Horiuchi, Teppei Morikawa, Kazuhiro Usui Abstract Rationale: Malignant peritoneal mesothelioma is a rare tumor with a poor prognosis and has no recommended therapy after first-line pemetrexed and platinum-based chemotherapy. Moreover, effects of immune checkpoint inhibitors on peritoneal mesothelioma remains to be…

Clinical Lung Cancer 2020 March 7 [Link] Lau B, Boyer M, Lee JH, Kao S Abstract INTRODUCTION: Studies of bevacizumab and pembrolizumab in the treatment of malignant pleural mesothelioma suggest anticancer efficacy; clinical trial populations are not reflective of real-world patients. We aimed to determine the proportion of real-world patients who would be eligible for…

Frontiers in Oncology 2020 February 21 [Link] de Gooijer CJ, Borm FJ, Scherpereel A, Baas P Abstract The only registered systemic treatment for malignant pleural mesothelioma (MPM) is platinum based chemotherapy combined with pemetrexed, with or without bevacizumab. Immunotherapy did seem active in small phase II trials. In this review, we will highlight the most…

Lung Cancer 2020 February 12 [Link] Zucali PA, Perrino M, De Vincenzo F, Giordano L, Cordua N, D’Antonio F, Santoro A Abstract OBJECTIVES: Second-line chemotherapy is not a standard of care in patients with malignant pleural mesothelioma (MPM) that progresses after first-line treatment with cisplatin and pemetrexed. In pre-clinical models, the combination of gemcitabine (GEM)…

Lung Cancer 2020 February 14 [Link] Bronte G, Delmonte A, Burgio MA, Verlicchi A, Puccetti M, Bravaccini S, Cravero P, Tumedei MM, Diano D, Rossi G, Ulivi P, Martinelli G, Crinò L Abstract OBJECTIVES: Treatment options for malignant pleural mesothelioma (MPM) are limited but some studies on immune checkpoint inhibitors (ICIs) in MPM have reported…

Journal of Oncology 2019 December 23 [Link] Borchert S, Suckrau PM, Wessolly M, Mairinger E, Hegedus B, Hager T, Herold T, Eberhardt WEE, Wohlschlaeger J, Aigner C, Bankfalvi A, Schmid KW, Walter RFH, Mairinger FD Abstract BACKGROUND: Malignant pleural mesothelioma (MPM) is a rare, predominantly asbestos-related and biologically highly aggressive tumor associated with a dismal…

Lung Cancer 2019 December 31 [Link] Lam WS, Creaney J, Chen FK, Chin WL, Muruganandan S, Arunachalam S, Attia MS, Read C, Murray K, Millward M, Spiro J, Chakera A, Gary Lee YC, Nowak AK Abstract OBJECTIVES: Currently, there is no optimal salvage therapy for patients with malignant pleural mesothelioma (MPM) who relapse after treatment…

Clinical Lung Cancer 2019 October 25 [Link] Paajanen J, Ilonen I, Lauri H, Järvinen T, Sutinen E, Ollila H, Rouvinen E, Lemström K, Räsänen J, Ritvos O, Koli K, Myllärniemi M Abstract BACKGROUND: Previous preclinical studies have shown that activin A is overexpressed in malignant pleural mesothelioma (MPM), associates with cancer cachexia, and is observed…

Cisplatin (Platinol ®)

Randomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901

Ganetespib in Combination with Pemetrexed-Platinum Chemotherapy in Patients with Pleural Mesothelioma (MESO-02): A Phase Ib Trial

Cisplatin Plus Pemetrexed Therapy and Subsequent Immune Checkpoint Inhibitor Administration for Malignant Peritoneal Mesothelioma Without Pleural Lesions: Case Report

Clinical Trials Eligibility of Patients With Malignant Pleural Mesothelioma: Use of Novel Therapies and Outcomes.

Immunotherapy in Malignant Pleural Mesothelioma.

A phase II study of the combination of gemcitabine and imatinib mesylate in pemetrexed-pretreated patients with malignant pleural mesothelioma.

Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement.

Screening of Pleural Mesothelioma Cell Lines for Kinase Activity May Identify New Mechanisms of Therapy Resistance in Patients Receiving Platin-Based Chemotherapy.

A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma.

Elevated Circulating Activin A Levels in Patients With Malignant Pleural Mesothelioma Are Related to Cancer Cachexia and Reduced Response to Platinum-based Chemotherapy.